Synmosa Biopharma (4114) — Free Cash Flow Generation Index
Synmosa Biopharma (4114) has a Free Cash Flow Generation Index of 0.68x as of December 2025. Free cash flow of NT$126.26 Million represents 1% of operating cash flow (NT$185.72 Million). Read Synmosa Biopharma (4114) financial obligations for a breakdown of total debt and financial obligations.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Synmosa Biopharma Free Cash Flow Generation Index (2015–2025)
Historical FCF Generation Index trend for Synmosa Biopharma across 9 annual periods. Explore Synmosa Biopharma (4114) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for Synmosa Biopharma (2015–2025)
Year-by-year Free Cash Flow Generation Index for Synmosa Biopharma. For the full company profile including market capitalisation, see Synmosa Biopharma market cap and net worth.
| Year | FCG Index | Free Cash Flow (TWD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.32x | NT$130.44 Million | NT$411.57 Million | NT$281.13 Million | ▼ -51.6% |
| 2024 | 0.65x | NT$510.97 Million | NT$780.62 Million | NT$269.65 Million | ▲ +38.4% |
| 2023 | 0.47x | NT$242.16 Million | NT$511.93 Million | NT$269.77 Million | ▼ -33.1% |
| 2022 | 0.71x | NT$445.92 Million | NT$630.25 Million | NT$129.29 Million | ▲ +4.0% |
| 2021 | 0.68x | NT$302.17 Million | NT$444.29 Million | NT$93.06 Million | ▲ +124.1% |
| 2020 | 0.30x | NT$77.20 Million | NT$254.40 Million | NT$154.41 Million | ▲ +101.4% |
| 2018 | -21.89x | NT$-350.16 Million | NT$16.00 Million | NT$314.43 Million | ▼ -883.9% |
| 2016 | 2.79x | NT$660.40 Million | NT$236.48 Million | NT$423.92 Million | ▼ -83.2% |
| 2015 | 16.65x | NT$392.86 Million | NT$23.60 Million | NT$369.26 Million | — |